Published in Clin Infect Dis on May 01, 1997
The clinical course of human immunodeficiency virus infection in genetically identical children. Clin Infect Dis (1997) 1.41
Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23
Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci (1988) 3.49
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis (1991) 3.16
Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med (1982) 3.08
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med (1999) 3.02
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Human immunodeficiency virus infection in children. J Pediatr (1989) 2.80
Antibiotic-resistant group JK bacteria in hospitals. J Clin Microbiol (1981) 2.71
Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J Clin Microbiol (1995) 2.51
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med (1986) 2.26
Detection of Candida antigen in sera of patients with candidiasis by an enzyme-linked immunosorbent assay-inhibition technique. J Clin Microbiol (1979) 2.13
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother (1995) 2.12
Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 2.11
Factors associated with disclosure of diagnosis to children with HIV/AIDS. Pediatr AIDS HIV Infect (1996) 2.09
Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome. J Pediatr (1990) 2.07
Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis (1994) 2.04
Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis (1988) 1.95
Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 1.95
Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. Annu Rev Microbiol (1988) 1.92
Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med (1988) 1.91
Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med (1988) 1.90
Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr (1995) 1.86
Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and granulocytopenia. Am J Med (1982) 1.84
A new tumour-derived transforming strain of Epstein-Barr virus. Nature (1978) 1.84
Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis (1991) 1.70
Cancer in children with primary or secondary immunodeficiencies. J Pediatr (1995) 1.70
Comparison of lysis-centrifugation with lysis-filtration and a conventional unvented bottle for blood cultures. J Clin Microbiol (1984) 1.67
Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J (1996) 1.66
Induced sputum to diagnose Pneumocystis carinii pneumonia in immunosuppressed pediatric patients. J Pediatr (1989) 1.63
Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother (1994) 1.61
Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med (1979) 1.61
Stimulatory effect of counterflow centrifugal elutriation in large-scale separation of peripheral blood monocytes can be reversed by storing the cells at 37 degrees C. J Clin Apher (1991) 1.61
Abnormal CT scans of the brain in asymptomatic children with acute lymphocytic leukemia after prophylactic treatment of the central nervous system with radiation and intrathecal chemotherapy. N Engl J Med (1978) 1.60
A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol (1990) 1.59
Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis (1992) 1.56
Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med (1995) 1.55
Smooth muscle tumors in children with human immunodeficiency virus infection. Pediatrics (1992) 1.50
Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother (1995) 1.48
Fungemia in children infected with the human immunodeficiency virus: new epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy. Clin Infect Dis (1995) 1.47
Leptotrichia buccalis bacteremia in patients with cancer: report of four cases and review. Rev Infect Dis (1991) 1.46
A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol (1992) 1.45
Pneumocystis carinii pneumonia despite prophylaxis in children with human immunodeficiency virus infection. J Pediatr (1991) 1.45
Pain in pediatric human immunodeficiency virus infection: incidence and characteristics in a single-institution pilot study. Pediatrics (1996) 1.44
Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis (1992) 1.42
Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrob Agents Chemother (1991) 1.41
Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J Infect Dis (1990) 1.41
Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis (1992) 1.39
Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin Infect Dis (1992) 1.38
Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. J Infect Dis (1994) 1.37
Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits. Antimicrob Agents Chemother (1990) 1.35
The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med (1989) 1.33
Perspective on the management of catheter-related infections in cancer patients. Pediatr Infect Dis (1986) 1.32
Clinical features and therapeutic interventions in 17 cases of Bacillus bacteremia in an immunosuppressed patient population. J Clin Microbiol (1987) 1.31
Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob Agents Chemother (1989) 1.30
Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. J Infect Dis (1992) 1.30
Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) (1992) 1.25
Disseminated infection with Mycobacterium gordonae: report of a case and critical review of the literature. Clin Infect Dis (1992) 1.25
IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Immunol (1997) 1.24
Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr (1992) 1.22
Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis (1995) 1.22
Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis (1996) 1.21
Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med (1981) 1.21
Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother (1994) 1.20
Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial. J Pediatr (1983) 1.17
Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother (1998) 1.16
Work-family issues and perceptions of stress among pediatric faculty and house staff. Ambul Pediatr (2002) 1.16
Health-care workers positive for hepatitis B surface antigen. Are their contacts at risk? N Engl J Med (1975) 1.15
Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis. J Clin Microbiol (1991) 1.14
Pharmacokinetics and tissue penetration of fluconazole in rabbits. Antimicrob Agents Chemother (1989) 1.14
Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr (1989) 1.12
Invasive zygomycosis due to Conidiobolus incongruus. Clin Infect Dis (1994) 1.12
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis (1996) 1.11
Orally administered clarithromycin for the treatment of systemic Mycobacterium avium complex infection in children with acquired immunodeficiency syndrome. J Pediatr (1994) 1.11
Controversies in the management of febrile neutropenic cancer patients. Cancer Invest (1988) 1.10
Pseudomonas infections in children with human immunodeficiency virus infection. Pediatr Infect Dis J (1992) 1.10
Effects of antifungal agents on the function of human neutrophils in vitro. Antimicrob Agents Chemother (1990) 1.08
Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother (1997) 1.07
Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis (1992) 1.07
Approaching the controversies in antibacterial management of cancer patients. Am J Med (1984) 1.06
Prolonged fever in children: review of 100 cases. Pediatrics (1975) 1.05
Hepatic abscess in cancer patients. Characterization and management. Arch Surg (1993) 1.05
Increasing incidence of Gram-positive sepsis in cancer patients. Med Pediatr Oncol (1978) 1.05
A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics (1998) 1.05
Pertussis in a previously immunized child with human immunodeficiency virus infection. J Pediatr (1989) 1.05
Infections due to Trichosporon species: new concepts in mycology, pathogenesis, diagnosis and treatment. Curr Top Med Mycol (1993) 1.04
Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. J Pediatr (1992) 1.04
Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) (1982) 1.03
Patterns of morphologic variation among isolates of Trichosporon beigelii. J Clin Microbiol (1990) 1.03
Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. J Pediatr (1994) 1.03
Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. J Pediatr (1999) 1.03
Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts. Rev Infect Dis (1990) 1.03
The utility of protected-environment regimens for the compromised host: a critical assessment. Prog Hematol (1977) 1.02
Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother (1994) 1.01
Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group. J Pediatr (1990) 0.98
Impairment of neutrophil antifungal activity against hyphae of Aspergillus fumigatus in children infected with human immunodeficiency virus. J Infect Dis (1993) 0.98
Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol (1996) 0.98